Xlife Sciences AGM Approves All Proposals, Highlights Veraxa Nasdaq Listing and Landsteiner Platform

In a significant show of shareholder support, Xlife Sciences (SIX: XLS) announced that all proposals were approved at its Annual General Meeting, with 54.3% of total share capital represented. Chairman David L. Deck highlighted the company's strengthened portfolio and key milestones, including the Nasdaq listing of portfolio company Veraxa Biotech (NASDAQ: VRXA) and the planned Landsteiner Scientific platform. These developments underscore the company's commitment to accelerating the identification and development of novel therapeutic approaches while improving global market access for its portfolio companies. The Landsteiner Scientific platform, described as a cornerstone of future innovation, integrates academic research with commercial development, positioning Xlife Sciences for its next growth phase.

Xlife Sciences, a Swiss firm focused on incubating and accelerating life sciences research from universities and institutions, aims to bridge the gap between research and healthcare markets. The company selects projects in technology platforms, biotech/therapies, medical technology, and AI/digital health. This strategic focus on high unmet medical needs is further supported by upcoming capital markets activities. The press release also features InvestorWire (IW), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides press release syndication and corporate communications solutions to reach investors and media. IBN’s network includes article and editorial syndication to 5,000+ outlets, enhancing brand awareness for clients.

The approval of all proposals at the AGM signals strong confidence in Xlife Sciences’ strategy, particularly the Landsteiner Scientific platform and the successful Nasdaq listing of Veraxa Biotech. These moves are set to accelerate the company's impact on global healthcare markets, addressing critical unmet medical needs. For more details, the full press release is available at https://ibn.fm/nfUvM.